Primary Graft Dysfunction clinical trials
The registry lists 26 studies for Primary Graft Dysfunction across more than 10 countries. 4 are recruiting or about to start. 22 of them are mainly about Primary Graft Dysfunction (how this is decided). Per ClinicalTrials.gov, last updated 2026-07-22.
Get an email when these change. Save the Primary Graft Dysfunction studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Policlinico Hospital (4) · University Hospital, Strasbourg, France (2) · University Health Network, Toronto (2) · University Hospital of Mont-Godinne (2) · University of Pennsylvania (2) · The Cleveland Clinic (1) · Guangzhou Institute of Respiratory Disease (1) · Azienda Ospedaliera di Padova (1)
What is being tested here
Drugs under test in Primary Graft Dysfunction studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Maraviroc | 1 | 0 | 1 |
| Treprostinil | 0 | 0 | 1 |
| Acetylcysteine | 0 | 0 | 1 |
| Sodium Nitrite | 0 | 0 | 1 |
| Calfactant | 0 | 1 | 1 |
| Ascorbic Acid | 0 | 0 | 1 |
| Thymoglobulin | 0 | 1 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 2
- Jun 2027Identifying Genetic Characteristics That Increase Risk of Primary Graft Dysfunction Following Lung Transplantation · University of Pennsylvania
- Jun 2027Risk Factors That Increase the Chance of Developing Primary Graft Dysfunction After Lung Transplantation · University of Pennsylvania
Who these studies take
Of the 4 Primary Graft Dysfunction studies recruiting now, 2 (50%) set no upper age limit and 2 (50%) stop at 75 or younger. 3 (75%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (25%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 4 (100%) | 4 (100%) |
| 30 | 4 (100%) | 4 (100%) |
| 40 | 4 (100%) | 4 (100%) |
| 50 | 4 (100%) | 4 (100%) |
| 65 | 4 (100%) | 4 (100%) |
| 75 | 3 (75%) | 3 (75%) |
| 85 | 2 (50%) | 2 (50%) |
Across all 26 studies, recruiting or not: 27% stop at 75 or younger and 8% at 65; 23% take children; 0% are for women only and 0% for men only; 8% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 26 of 26. search them.
- Risk Factors That Increase the Chance of Developing Primary Graft Dysfunction After Lung TransplantationRecruitingNCT005523571 country
- Prospective Reduction Of Transplant Complications Through Enhanced Preservation Therapy to Prevent Primary Graft DysfunctionRecruitingNCT07230886Not applicable1 country
- This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft DysfunctionRecruitingNCT06853223Phase 21 country
- Exhaled Breath Particles in Lung TransplantationRecruitingNCT053751491 country
- Identifying Genetic Characteristics That Increase Risk of Primary Graft Dysfunction Following Lung TransplantationActive, not recruitingNCT004578471 country
- Biomolecular Phenotyping of Lung Transplant RecipientsCompletedNCT061255351 country
- Point-of-care Management of Coagulopathy in Lung TransplantationTerminatedNCT035989071 country
- Identifying Optimal PEEP After Lung TransplantationCompletedNCT05691205Not applicable1 country
- Subcutaneous Treprostinil as a Bridge to Lung Transplantation in Severe Pulmonary Hypertension: A Single-Arm Retrospective StudyCompletedNCT06605326Phase 4
- Observational Study on the Variation of Ascorbic Acid in Patients Undergoing Solid Organ TransplantationActive, not recruitingNCT063952591 country
- CLAD: Finding Biomarkers to Predict Rejection and/ or Outcome After Lung TransplantationTerminatedNCT045583331 country
- Primary Graft Dysfunction, Pronation, Bilateral Lung TransplantsCompletedNCT06159933Not applicable1 country
- Perioperative Vitamin C Lung TransplantWithdrawnNCT04505878Phase 2
- Lung and Diaphragm Ultrasound in the Early Postoperative Course Following Lung TransplantationCompletedNCT04891094Not applicable1 country
- Intraoperative Versus Postoperative Thymoglobulin in Lung TransplantationWithdrawnNCT00592306Phase 31 country
- Bypass vs. Ecmo in Lung Transplantation (BELT)TerminatedNCT030215381 country
- Study in Intensive Care Patients Regarding the Effect of Inhaled AP-301 After Primary Graft Dysfunction After Lung TransplantationCompletedNCT02095626Phase 21 country
- Sodium Nitrite in Lung Transplant Patients to Minimize the Risk of Pulmonary Graft DysfunctionTerminatedNCT01715883Phase 21 country
- Measurement of Extravascular Lung Water to Detect and Predict Primary Graft Dysfunction Following Lung TransplantStatus unknownNCT016052141 country
- Heart Transplant and Primary Transplant Dysfunction: a Retrospective Analysis of the Strasbourg ExperienceStatus unknownNCT031568941 country
- Lung PGD Biomarkers in Organ DonorsStatus unknownNCT03089489
- Pneumoproteins Expression in the Organ DonorCompletedNCT020320691 country
- Ex-Vivo Lung Perfusion to Increase the Number of Organs for TransplantationCompletedNCT01967953Phase 11 country
- Use of N-Acetylcysteine During Liver ProcurementCompletedNCT01394497Phase 21 country
- Quantifying Physical and Biochemical Factors That Contribute to Primary Graft Dysfunction After Lung TransplantationStatus unknownNCT011518261 country
- The Use of Surfactant in Lung Transplantation: A Randomized Control Pilot StudyStatus unknownNCT00506532Phase 2/31 country